Kim Young-Chae, Fang Sungsoon, Byun Sangwon, Seok Sunmi, Kemper Byron, Kemper Jongsook Kim
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL.
Hepatology. 2015 Jul;62(1):220-31. doi: 10.1002/hep.27677. Epub 2015 Feb 27.
Bile acids (BAs) function as endocrine signaling molecules that activate multiple nuclear and membrane receptor signaling pathways to control fed-state metabolism. Since the detergent-like property of BAs causes liver damage at high concentrations, hepatic BA levels must be tightly regulated. Bile acid homeostasis is regulated largely at the level of transcription by nuclear receptors, particularly the primary BA receptor, farnesoid X receptor, and small heterodimer partner, which inhibits BA synthesis by recruiting repressive histone-modifying enzymes. Although histone modifiers have been shown to regulate BA-responsive genes, their in vivo functions remain unclear. Here, we show that lysine-specific histone demethylase1 (LSD1) is directly induced by BA-activated farnesoid X receptor, is recruited to the BA synthetic genes Cyp7a1 and Cyp8b1 and the BA uptake transporter gene Ntcp, and removes a gene-activation marker, trimethylated histone H3 lysine-4, leading to gene repression. Recruitment of LSD1 was dependent on small heterodimer partner, and LSD1-mediated demethylation of trimethylated histone H3 lysine-4 was required for additional repressive histone modifications, acetylated histone 3 on lysine 9 and 14 deacetylation, and acetylated histone 3 on lysine 9 methylation. A BA overload, feeding 0.5% cholic acid chow for 6 days, resulted in adaptive responses of altered expression of hepatic genes involved in BA synthesis, transport, and detoxification/conjugation. In contrast, adenovirus-mediated downregulation of hepatic LSD1 blunted these responses, which led to substantial increases in liver and serum BA levels, serum alanine aminotransferase and aspartate aminotransferase levels, and hepatic inflammation.
This study identifies LSD1 as a novel histone-modifying enzyme in the orchestrated regulation mediated by the farnesoid X receptor and small heterodimer partner that reduces hepatic BA levels and protects the liver against BA toxicity.
胆汁酸(BAs)作为内分泌信号分子,可激活多种核受体和膜受体信号通路,以控制进食状态下的新陈代谢。由于胆汁酸的去污剂样特性在高浓度时会导致肝损伤,因此肝脏胆汁酸水平必须受到严格调控。胆汁酸稳态主要在转录水平由核受体调节,特别是初级胆汁酸受体法尼醇X受体(FXR)和小异二聚体伴侣(SHP),后者通过募集抑制性组蛋白修饰酶来抑制胆汁酸合成。尽管组蛋白修饰剂已被证明可调节胆汁酸反应性基因,但其体内功能仍不清楚。在此,我们表明赖氨酸特异性组蛋白去甲基化酶1(LSD1)由胆汁酸激活的法尼醇X受体直接诱导,被募集到胆汁酸合成基因Cyp7a1和Cyp8b1以及胆汁酸摄取转运体基因Ntcp,并去除基因激活标记三甲基化组蛋白H3赖氨酸-4,导致基因抑制。LSD1的募集依赖于小异二聚体伴侣,并且LSD1介导的三甲基化组蛋白H3赖氨酸-4去甲基化是额外的抑制性组蛋白修饰、赖氨酸9和14上的乙酰化组蛋白3去乙酰化以及赖氨酸9上的乙酰化组蛋白3甲基化所必需的。胆汁酸过载,即喂食0.5%胆酸饲料6天,导致参与胆汁酸合成、转运和解毒/结合的肝脏基因表达改变的适应性反应。相反,腺病毒介导的肝脏LSD1下调减弱了这些反应,导致肝脏和血清胆汁酸水平、血清丙氨酸转氨酶和天冬氨酸转氨酶水平以及肝脏炎症大幅增加。
本研究确定LSD1是法尼醇X受体和小异二聚体伴侣介导的协调调节中的一种新型组蛋白修饰酶,可降低肝脏胆汁酸水平并保护肝脏免受胆汁酸毒性。